ERBB2 and gastric cancer: We have provided a foundation for a path forward to the clinic and suggest that next steps include a targeted approach that would include testing of DIACC3010 in additional models of HER2-negative GC in combination with standard of care chemotherapeutics and investigation of DEGs or signature, PIK3CA mutations, and low basal pERK as potential predictive markers of sensitivity.